Microba Life Sciences (MAP) Q1 2025 TU earnings summary

Executive summary

• Revenue reached $3.65 million for Q1 FY25, up 239% year-over-year, driven by strong MetaXplore adoption in Australia and initial UK sales.

• Cash receipts were $5.07 million, up 184% year-over-year.

• MetaXplore test sales in Australia grew 101% year-over-year to 1,832 units, with 487 ordering clinicians (+81%).

• UK business transitioned to MetaXplore, with first orders received in October and sales force doubled to support growth.

• Strategic hires include a new Chief Growth Officer and Chief Product Officer to accelerate global expansion.

Financial highlights

• Q1 FY25 revenue of $3.65 million, up 239% year-over-year.

• Cash receipts of $5.07 million, up 184% year-over-year.

• Personal testing & supplements revenue reached $3.39 million (+316% year-over-year); research testing revenue was $0.26 million (-1%).

• Cash and equivalents at 30 September 2024 were $16.4 million, with an additional $6 million expected from R&D tax incentive.

• Annualised run rate of 7,328 MetaXplore tests sold in Australia.

Outlook and guidance

• Expectation of continued strong growth in Australia and the UK, with MetaXplore full access in the UK set for 2025.

• Q2 started with record sales, and both testing and supplement sales in the UK are ahead of September.

• Focus on advancing therapeutics to phase two trials and active global partnering.

• Anticipate meaningful sales volume and revenue growth from MetaPanel and MetaXplore in FY25.

• Focus on US reimbursement path and further clinical adoption in diagnostics.